Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8

6 clinical trials · Condition

Record	Firm	Date
Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers (NCT05296005)	Ohio State University Comprehensive Cancer Center	2025-12-31
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer (NCT04929392)	City of Hope Medical Center	2022-01-25
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery (NCT04391049)	NRG Oncology	2021-12-02
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma (NCT04097028)	Roswell Park Cancer Institute	2019-12-20
Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma (NCT03784326)	M.D. Anderson Cancer Center	2019-02-19
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer (NCT03776487)	M.D. Anderson Cancer Center	2019-01-07

Every clearance here is in the API, with alerts when new ones post.